Functional Assessment of Biomarkers in Gemcitabine-Treated Pancreatic Cancer with Specific Focus on Nucleoside Transporter ENT1

Functional Assessment of Biomarkers in Gemcitabine-Treated Pancreatic Cancer with Specific Focus on Nucleoside Transporter ENT1

Bibliographic Details
Main Author:	Roppel, Sebastian
Other Authors:	Schirmer, Markus Dr.
Format:	Doctoral Thesis
Language:	English
Published:	2013
Subjects:	610 Gemcitabine SLC29A1 ENT1 Gemcitabine transport Medizin (PPN619874732)
Online Access:	http://hdl.handle.net/11858/00-1735-0000-0001-BC18-5 http://nbn-resolving.de/urn:nbn:de:gbv:7-11858/00-1735-0000-0001-BC18-5-5

Similar Items

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
by: Guo ZY, et al.
Published: (2018-08-01)

Variabilität des Therapieansprechens von Gemcitabin bei Pankreaskarzinom: Identifizierung relevanter Genpolymorphismen
by: Schaudinn, Alexander
Published: (2013)

Identifizierung von Biomarkern für die Prognose der Gemcitabin-Therapie beim Pankreaskarzinom: RNA-, DNA- und Immunhistochemische- Analysen
by: Zimmer, Christian
Published: (2015)

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
by: Jerome Raffenne, et al.
Published: (2019-11-01)

Analyse des Notfallaufkommens an der HNO-Klinik der Universitätsmedizin Göttingen im Jahr 2011
by: Petersen, Anna Lena
Published: (2015)

Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)
by: Daisaku Yamada, et al.
Published: (2021-08-01)

Langzeitergebnisse der Erhaltungstherapie mit Gemcitabin nach Cisplatin-basierter adjuvanter Chemotherapie des operativ behandelten muskelinfiltrierenden Urothelkarzinoms
by: Svistunov, Andrey
Published: (2017)

Combining gemcitabine with checkpoint kinase inhibitors to sensitize pancreatic tumors
by: Saini, Priyanka
Published: (2015)

Imexon and Gemcitabine: Mechanisms of Synergy against Human Pancreatic Cancer
by: Roman, Nicholas
Published: (2005)

Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
by: Gong DJ, et al.
Published: (2013-07-01)

Girdin Knockdown Increases Gemcitabine Chemosensitivity to Pancreatic Cancer by Modulating Autophagy
by: Sheng Wang, et al.
Published: (2021-03-01)

Stromal and epithelial mechanisms of chemotherapeutic resistance in pancreatic cancer
by: Patzak, Melanie Susanne
Published: (2019)

Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters
by: Ying-Si Wu, et al.
Published: (2021-04-01)

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
by: Ma Yue, et al.
Published: (2011-03-01)

Epibrassinolide Promotes the Apoptotic Potential of Gemcitabine in Pancreatic Cancer Cells
by: Fadina Kuryayeva, et al.
Published: (2019-12-01)

Gemcitabine-Induced Cardiotoxicity in Patients Receiving Adjuvant Chemotherapy for Pancreatic Cancer: A Case Series
by: Salma Alam, et al.
Published: (2018-04-01)

Pancreatic Cancer Chemoresistance to Gemcitabine
by: Manoj Amrutkar, et al.
Published: (2017-11-01)

Tissue distribution of crizotinib and gemcitabine combination in a patient-derived orthotopic mouse model of pancreatic cancer
by: Richard J. Honeywell, et al.
Published: (2016-12-01)

Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling
by: Zhengle Zhang, et al.
Published: (2018-11-01)

A [60]fullerene nanoconjugate with gemcitabine: synthesis, biophysical properties and biological evaluation for treating pancreatic cancer
by: Paweł Nalepa, et al.
Published: (2020-02-01)

Gemcitabine and S-1 Combination Chemotherapy in Patients with Advanced Biliary Tract Cancer:A Retrospective Study
by: Kazuhito Mita, et al.
Published: (2010-12-01)

Gemcitabine-induced cardiomyopathy: a case report and review of the literature
by: Khan, Muhammad, et al.
Published: (2014)

Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma
by: Karen E. Mulder, et al.
Published: (2011-09-01)

Die Rolle der Linker-Domäne von STAT1 bei der Regulation transkriptioneller Antworten im Interferon-Signalweg
by: Bolten, Jana Christin
Published: (2013)

Der Einfluss des DDR1+/-/NPHS2+/R140Q-Genotyps auf die Interaktion zwischen glomerulärer Basalmembran und Schlitzmembran im Tiermodell
by: Schütte, Peter
Published: (2014)

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
by: Jie Xu, et al.
Published: (2018-10-01)

Genetisch bedingte Variabilität der Expression von Genen des TGFß-Signalwegs und deren Bedeutung für die Zellvitalität: Untersuchungen in T-Lymphozyten, immortalisierten B-Lymphozyten und Fibroblasten
by: Neumann, Michael
Published: (2013)

Verbesserung der Lebensqualität von Patienten nach bimaxillärer Umstellungsosteotomie durch Genioplastik
by: Lehmann, Antje
Published: (2017)

Langzeitergebnisse nach totaler extraperitonealer Hernioplastik (TEP) bei Patienten mit dem Erstereignis einer Leistenhernie
by: Malorny, Lara
Published: (2018)

RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine
by: Chen Y, et al.
Published: (2018-09-01)

Toxicoderma by gemcitabine: About a case
by: Flora López-López, et al.
Published: (2018-02-01)

Gemcitabine Combination Nano Therapies for Pancreatic Cancer
by: Kamalika Samanta, et al.
Published: (2019-11-01)

Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel
by: Hakon Blomstrand, et al.
Published: (2020-10-01)

Inhibition of the Receptor for Advanced Glycation End Products Enhances the Cytotoxic Effect of Gemcitabine in Murine Pancreatic Tumors
by: Priyanka Swami, et al.
Published: (2021-04-01)

Gemcitabine-associated acute lipodermatosclerosislike eruption: An underrecognized phenomenon
by: Amit Mittal, BA, et al.
Published: (2017-05-01)

THE DIFFERENCES OF APOPTOSIS EFFECTS BETWEEN COMBINATION OF MELOXICAM WITH GEMCITABINE-CARBOPLATIN CHEMOTHERAPY COMPARED TO GEMCITABINE-CARBOPLATIN CHEMOTHERAPY ALONE IN UROTHELIAL CARCINOMA CULTURE CELLS
by: Ananta Cahyo Nugroho, et al.
Published: (2019-01-01)

Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
by: Elena Ferris Villanueva, et al.
Published: (2015-02-01)

LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal AdenocarcinomaSummary
by: Yin-Xin Zhu, et al.
Published: (2020-01-01)

RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy
by: Zhenxing Yang, et al.
Published: (2019-07-01)

High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma
by: Lv W, et al.
Published: (2016-05-01)